Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Interest in CD3 bispecifics grows

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Aug 07, 2023 12:39pm

193 Views

Post# 35576265

Interest in CD3 bispecifics grows

August 07, 2023 -

The FDA has cleared BioCity Bioparma's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb).

https://www.biospace.com/article/releases/biocity-announces-fda-clearance-of-investigational-new-drug-application-for-its-first-in-class-cd3-egfr-bispecific-antibody/

<< Previous

Bullboard Posts

Next >>

HPQ Silicon updates shareholders on Fumed Silica Reactor developments